血清FGFR-4、CCL11、CA125检测对分化型甲状腺癌的诊断价值  

The Diagnostic Value of Serum FGFR-4,CCL11 and CA125 Detection for Differentiated Thyroid Cancer

作　　者：宋晏 张洁 付伟 SONG Yan;ZHANG Jie;FU Wei(Department of Nuclear Medicine,3201 Hospital of Hanzhong,Hanzhong 723000,China)

机构地区：[1]陕西省汉中市三二〇一医院核医学科,陕西汉中723000

出　　处：《标记免疫分析与临床》2024年第6期1033-1037,1048,共6页Labeled Immunoassays and Clinical Medicine

基　　金：2022年度陕西省医学科学研究课题计划(编号:20220911)。

摘　　要：目的探究血清成纤维生长因子受体4(FGFR-4)、嗜酸性粒细胞趋化因子(CCL11)、糖类抗原(CA125)检测对分化型甲状腺癌的诊断价值。方法选取2019年2月至2023年2月来我院治疗的133例确诊为分化型甲状腺癌的患者为观察组,选同期来我院治疗的108例甲状腺良性病变患者为良性病变组,另选取同期来我院体检的120例健康者为对照组。采用酶联免疫吸附测定法(ELISA)测定血清FGFR-4、CCL11水平,采用电化学发光法测定CA125水平;受试者工作特征(ROC)曲线分析血清FGFR-4、CCL11、CA125水平对分化型甲状腺癌的诊断价值。结果甲状腺癌组和良性病变组患者血清FGFR-4、CCL11、CA125水平与对照组相比均显著升高,且甲状腺癌组与良性病变组相比均显著升高(P<0.05);甲状腺癌组患者手术后血清FGFR-4、CCL11、CA125水平均显著下降(P<0.05);血清FGFR-4、CCL11、CA125水平在低分化、有淋巴结转移、III+IV期患者中的水平显著升高(P<0.05);血清FGFR-4、CCL11、CA125诊断分化型甲状腺癌的曲线下面积(AUC)分别为0.793、0.808、0.647,3项联合诊断的AUC为0.867,3项联合诊断优于各个指标单独诊断(Z_(二者联合vs FGFR-4)=2.334、Z_(二者联合vs CCL11)=1.966、Z_(二者联合vs CA125)=5.132,P=0.020、0.048、0.000)。结论分化型甲状腺癌患者血清FGFR-4、CCL11、CA125水平均上调,且血清FGFR-4、CCL11、CA125水平与分化程度、淋巴结转移情况以及TNM分期有关,3项联合诊断分化型甲状腺癌具有更高的诊断价值。Objective To explore the diagnostic value of serum fibroblast growth factor receptor-4(FGFR-4),CC chemokine ligand 11(CCL11)and carbohydrate antigen(CA125)detection for differentiated thyroid cancer.Methods From February,2019 to February,2023,133 confirmed differentiated thyroid cancer patients treated in our hospital were collected as the thyroid cancer group,while 108 patients with benign thyroid lesions who visited our hospital for treatment were regarded as the benign lesion group,and 120 healthy individuals who visited our hospital for physical examination were enrolled as the reference group.Enzyme-linked immunosorbent assay(ELISA)was applied to detect serum levels of FGFR-4 and CCL11 and electrochemiluminescence was applied to measure CA125 level;Receiver operating characteristic(ROC)curve was drawn to evaluate the diagnostic value of serum FGFR-4,CCL11 and CA125 levels for differentiated thyroid cancer.Results Serum levels of FGFR-4,CCL11 and CA125 in the thyroid cancer group and benign lesion group were significantly higher than the reference group,while the thyroid cancer group were significantly higher than the benign lesion group(P<0.05);Serum levels of GFR-4,CCL11 and CA125 in the thyroid cancer group significantly decreased after surgery(P<0.05);Levels of serum FGFR-4,CCL11 and CA125 in patients with low differentiation,lymph node metastasis and stage III+IV were significantly higher than those in patients with medium to high differentiation,no lymph node metastasis and stage I+II(P<0.05);The area under the curve(AUC)of serum FGFR-4,CCL11 and CA125 for diagnosing differentiated thyroid cancer were 0.793,0.808,and 0.647,respectively,while the AUC of combined diagnosis of the three was 0.867,and the combined diagnosis of the three was superior to the individual diagnosis of each indicator(Z_(combination vs FGFR-4)=2.334,Z_(combination vs CCL11)=1.966,Z_(combination vs CA125)=5.132,P=0.020,0.048,0.000).Conclusion Serum levels of FGFR-4,CCL11 and CA125 in patients with differentiated thyroid cancer are

关 键 词：分化型甲状腺癌 成纤维生长因子受体4 嗜酸性粒细胞趋化因子 糖类抗原 

分 类 号：R736.1[医药卫生—肿瘤]